Pharmaceutical research and development: what do we get for all that money?

Pharmaceutical research and development: what do we get for all that money?

Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ (Online) 2012-08, Vol.345 (aug07 1), p.e4348-e4348
Hauptverfasser: Light, Donald W, Lexchin, Joel R
Format: Artikel
Sprache:eng
Schlagworte:
Biomedical Research - economics
Cost-Benefit Analysis
Costs
Diffusion of Innovation
Drug Discovery - economics
Drug Discovery - trends
Drug-Related Side Effects and Adverse Reactions - economics
FDA approval
Innovations
Medical innovations
Medical research
Models, Economic
Pharmaceutical industry
Pharmacology - economics
Prescription drugs
R&D
Reinforcement
Research & development
Research & development expenditures
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say Donald Light and Joel Lexchin, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones
ISSN:0959-8138
1756-1833
1756-1833
DOI:10.1136/bmj.e4348